Integrative Analysis of CRC Liver Metastasis

Da Fu1,000 enrolled

Overview

The investigators will perform integrative analysis of CRC liver metastasis

The investigators will analyzed proteomes of paired normal colorectal tissues and colorectal cancer (CRC) with or without liver metastasis, sequenced transcriptomes, performed whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal colorectal tissue, primary colorectal carcinoma, and its synchronous matched liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Metastasis

Interventions

normal colorectal tissuesOTHER

The investigators will extract total protein, DNA and RNA from these groups.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≤ 75 years with histologically proven CRC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * World Health Organization (WHO) performance status of \>1 * Prior cancer chemotherapy

Locations (2)

Ganzhou City People's Hospital

Ganzhou, Jiangxi, China

RECRUITING

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

5 years overall survival

Time frame: 5 years

Secondary Outcomes

5 years disease-free survival

Time frame: 5 years

Central Contacts

Da Fu, Ph.D.

CONTACT

021-66301604 shsyiec@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.